EyePoint Q2 2026 earnings: Phase 3 spending widens the net loss

EyePoint (Nasdaq: EYPT) reported Q2 2026 revenue of $0.5 million, down from $5.3 million a year earlier, while diluted loss per share widened to $1.09 from $0.85. The larger loss reflected increased spending on DURAVYU Phase 3 trials and manufacturing scale-up, while cash and investments declined to $180 million.

Core financial results

The revenue decline largely reflected the comparison with prior-year deferred revenue recognition related to EyePoint’s 2023 agreement covering YUTIQ product rights. EyePoint recorded no product sales during the quarter, leaving license and collaboration revenue as its only reported revenue source.

Operating expenses increased about 45% to $97.9 million. Research and development was the main driver, rising about 51% as the company funded pivotal wet AMD and diabetic macular edema trials for DURAVYU.

Dollar figures are rounded from EyePoint’s unaudited financial statements for the three months ended June 30.

Clinical program progress

DURAVYU’s wet AMD program is approaching two pivotal data readouts. The identical Phase 3 LUGANO and LUCIA non-inferiority trials enrolled more than 900 patients combined and compare six-month DURAVYU redosing with on-label aflibercept. LUGANO topline data are expected in August 2026, followed by LUCIA results in Q4 2026.

A Data Safety Monitoring Committee recommended in May that both trials continue without protocol modifications. EyePoint said masked interim safety findings remained consistent with the safety profile observed in four previously completed DURAVYU studies involving more than 190 patients.

In diabetic macular edema, the Phase 3 COMO and CAPRI trials completed enrollment of more than 480 patients in five months. Both studies use a non-inferiority design against on-label aflibercept, with topline results expected in Q4 2027.

Phase 3 spending widens losses ahead of wet AMD data

The quarter’s financial results show the cost of running multiple pivotal programs at the same time. R&D expense was the largest component of operating costs, while manufacturing-facility scale-up also contributed to the increase. The resulting $97.4 million operating loss was only partly offset by $2.9 million of net non-operating income.

Cash, cash equivalents and marketable securities declined from $223 million on March 31 to $180 million on June 30, a sequential decrease of about $43 million. The company did not provide quarterly operating or free cash flow, so the change in liquidity should not be treated as a direct cash-burn measure.

Financial outlook

EyePoint expects its June 30 cash and investment balance to fund operations into Q4 2027. That timeline extends beyond the two planned wet AMD Phase 3 readouts in 2026, although it reaches only into the same quarter currently targeted for the DME trial results.

The outlook is based on the $180 million of cash, cash equivalents and marketable securities held at the end of Q2 2026.

Recent insider transactions

Reported insider data for the past six months show 42,854 shares purchased across eight transactions and 12,187 shares sold across four transactions, producing net purchases of 30,667 shares. The following dated records are presented without drawing conclusions about insiders’ views of the company.

Risks investors should monitor

• Pivotal clinical results: LUGANO and LUCIA must deliver results sufficient to support DURAVYU’s development and regulatory pathway. The favorable interim safety review does not establish efficacy or guarantee approval.
• Cash-runway timing: The projected runway extends into Q4 2027, the same quarter targeted for COMO and CAPRI results. Higher costs, delays or additional development work could increase financing requirements.
• Continued expense growth: R&D spending and manufacturing scale-up drove a substantial increase in operating expenses. These costs may remain elevated while multiple Phase 3 programs are active.
• Limited current revenue: Q2 revenue was only $0.5 million, with no product sales. EyePoint therefore has little operating revenue available to offset clinical and manufacturing expenditures.

Summary

EyePoint’s Q2 2026 loss widened as the company increased investment in DURAVYU’s pivotal trials and manufacturing capabilities, while revenue fell because of an unfavorable licensing-revenue comparison. The central near-term focus is now clinical rather than commercial: LUGANO data are expected in August, LUCIA follows in Q4, and the available liquidity is expected to support operations into Q4 2027.